Updated December 2020, this database reveals the identities of 107 CAR-T companies worldwide, with detailed company information.
CAR-T companies are on the rise, supported by growing investment flowing into CAR-T product development and landmark approvals of CAR-T cell therapies by the U.S. FDA, European Medicines Agency (EMA), Health Canada, Australian TGA, and others. There have also been major acquisitions within the CAR-T space, with Celgene snagging Juno Therapeutics for a shocking $9 billion in and Gilead acquiring Kite Pharma for an astounding $11.9 billion.
This is a global database of CAR-T companies that we originally developed for our own purposes.
Because more and more of our readers have been requesting access to this comprehensive list of CAR-T cell therapy companies, we are making it accessible to the public – for a limited-time only.
Features of the CAR-T Company Database (107 Companies)
Chimeric antigen receptors (CARs) are genetically engineered allogeneic cells that are developed in the laboratory and infused into a patient, to help in detecting and fighting cancer cells. The protein constructs stimulate anti-cancer T-cells which in turn boost a patient’s immune system.
The database features the following information for 100+ CAR-T market competitors:
- Company Name
- CAR-T Technology
- Disease Targets
- Description of CAR-T Involvement
- City / State
- Link to CAR-T Programs
- Company Website
Use this list of CAR-T companies to:
- Identify global competitors within the CAR-T marketplace
- Quantify CAR-T products in late-stage development
- Reveal preclinical & clinical programs supporting CAR-T development
- Identify regions that are “hotspots” for CAR-T cell therapies
- Understand partnerships and co-development programs for CAR-T technologies
- Identify M&A activity within the CAR-T industry
Database of CAR-T Cell Therapy Companies
It takes our team of analysts hours of research to uncover these CAR-T cell therapy companies from across the globe and requires translating company sites and clinical trial programs from dozens of languages.
Thankfully, we have a talented and multilingual team who is up to the task of listing all known CAR-T cell therapy companies worldwide.
Because we continuously update this database to reflect new competitors entering the CAR-T cell therapy marketplace, we are confident it will be an invaluable resource to your group.
With the value of recent CAR-T IPO’s nearing $1.5 billion, CAR-T financing rounds approaching $2 billion, and $20 billion of market capitalization from CAR-T companies in recent years, this is clearly a hot market segment.
Would you benefit from knowing the identities of CAR-T market competitors worldwide, as well as being informed about historic CAR-T funding events?
If so, you can claim this CAR-T database for only $49 and get the CAR-T Funding Brief for FREE (a $49 value).
Both products were updated as of December 15, 2019.
Act now and both products will immediately be available for download, with printing rights allowed.
Of course, your investment is backed by our 60-Day Money Back Guarantee.
If you’ve claimed this database in the past 12 months, email [email protected] to receive a free update of it.